A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Janssen Research & Development, LLC
Study ID
NCT07266441
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • JNJ-79635322 — DRUG
    JNJ-79635322 will be administered as an injection under the skin.

Study Details

The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.

Key Dates

Start date
Feb 8, 2026
Status verified
Jun 2026
Primary completion
Jun 14, 2027
Completion
Dec 12, 2028

Study Design

Enrollment
157 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: JNJ-79635322
    Participants will receive JNJ-79635322 as an injection under the skin.

Primary Outcome Measure

Overall Response Rate (ORR) [ Time Frame: Up to 2 years and 9 months ]

Central Contacts

Locations (29)

FacilityCityStateZIPSite coordinators
O Neal Comprehensive Cancer Center at UABBirminghamAlabama35294-
Banner MD Anderson Cancer CenterGilbertArizona85234-
City of HopeDuarteCalifornia91010-
City of Hope Orange County Lennar Foundation Cancer CenterIrvineCalifornia92618-
Cancer and Blood Specialty ClinicLos AlamitosCalifornia90720-
University of California San FranciscoSan FranciscoCalifornia94143-
Rocky Mountain Cancer CentersAuroraColorado80012-
Colorado Blood Cancer InstituteDenverColorado80218-
Cancer Specialists of North FloridaJacksonvilleFlorida32256-
Emory UniversityAtlantaGeorgia30322-
Northside Hospital Cancer InstituteAtlantaGeorgia30342-
Cancer Care Specialists of Central IllinoisO'FallonIllinois62269-
University of IowaIowa CityIowa52242-
Mission Cancer BloodWaukeeIowa50263-
Massachusetts General HospitalBostonMassachusetts02114-
Rutgers Cancer InstituteNew BrunswickNew Jersey08901-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
Cleveland Clinic FoundtationClevelandOhio44195-
Oncology Associates of Oregon PC Willamette Valley Cancer InstituteEugeneOregon97401-
University of PennsylvaniaPhiladelphiaPennsylvania19104-
SCRI Oncology PartnersNashvilleTennessee37203-
Tennessee Oncology, PLLCNashvilleTennessee37203-
Texas OncologyAustinTexas78705-
MD Anderson Cancer CenterHoustonTexas77030-
Oncology Consultants TexasHoustonTexas77030-
Texas Oncology - NortheastTylerTexas75702-
Virginia Cancer SpecialistsFairfaxVirginia22031-
Virginia Oncology AssociatesNorfolkVirginia23502-
NorthWest Medical Specialties, PLLCTacomaWashington98405-

Find similar trials in Birmingham, AL

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
O Neal Comprehensive Cancer Center at UAB· Birmingham, ALBanner MD Anderson Cancer Center· Gilbert, AZCity of Hope· Duarte, CACity of Hope Orange County Lennar Foundation Cancer Center· Irvine, CACancer and Blood Specialty Clinic· Los Alamitos, CAUniversity of California San Francisco· San Francisco, CA

Related Studies